Philips Launches Azurion with FlexArm to Set New Standard for the Future of Image-Guided Procedures

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Azurion with FlexArm, to set a new standard for patient imaging and positioning flexibility for image-guided procedures.

During increasingly complex interventions, clinicians need to quickly and easily visualize critical anatomy and identify changes to the patient during the procedure. Azurion with FlexArm includes a set of innovations that makes it easier for the clinician to perform imaging across the whole patient in both 2D and 3D. As the clinician moves the system, the image beam automatically maintains alignment with the patient, allowing more consistent visualization and enabling them to keep their focus on the treatment.

"With FlexArm, Philips' engineers have overcome near-impossible geometric and mechanical barriers to enable clinicians to achieve clinical excellence in image-guided therapy," said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). "FlexArm enables us to dramatically optimize procedures around the patient: we can get the optimal view of what's going on inside the patient without encumbering all of the clinicians that are working around the table. The result is an innovation that’s not only clinically important but also very simple and intuitive to use - a critical factor in the heat of a complex procedure."

The range and complexity of diseases that can be treated with minimally invasive procedures continues to expand. Correspondingly, the procedures themselves are also becoming more complex, requiring more physicians from different disciplines to be at the patient’s tableside, working together in a highly coordinated way. As a result, the clinical team is required to carry out increasingly challenging procedures in a highly constrained environment.

Azurion with FlexArm's innovative design provides exceptional flexibility and intuitive control. Powered by a unique smart kinematic engine, the system moves on eight different axes, all controlled with its single 'Axsys' controller. Simulation tests with clinicians have demonstrated the system's potential to significantly reduce the repositioning of the patient, staff and equipment to improve access for minimally invasive procedures, including those that enter the body through the patient's wrist ('radial access'), and to reduce the risk of unintentional pulling of wires and tubes, as well as significant time savings [1]. The system is ideally suited for Hybrid ORs that cater to multiple specialties in one room, such as a combination of surgical and endovascular procedures.

"Two years on from its launch, Azurion is now established as our leading platform for interventional procedures, favored by clinicians for its intuitive, seamless approach that enables them to focus on treating the patient, and by hospital administrators for its positive impact on productivity and efficiency," said Ronald Tabaksblat, Business Leader Image Guided Therapy Systems, Philips. "FlexArm is the natural next step in our Azurion innovation journey, combining clinical and operational benefits to improve patient care and reduce costs, while opening up opportunities for new image-guided procedures as the field continues grow."

Azurion with FlexArm is the latest innovation in Philips' unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions. As the range of diseases that can be treated with minimally invasive procedures continues to expand and the procedures themselves become more efficient, the patient's treatment experience continues to improve. They experience less trauma, and as a result their stay in hospital can be dramatically reduced - often returning home after one night in hospital, and for some procedures even leaving the hospital on the same day.

Since its global launch in February 2017, over 450.000 patients have been treated in more than 80 countries using a Philips Azurion system. The Philips Azurion 7 C20 with FlexArm is CE marked and has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2017 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

1. Uselab simulation test with 15 clinicians.

Most Popular Now

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...

OmicsFootPrint: Mayo Clinic's AI To…

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images. The details of the tool...

Testing AI with AI: Ensuring Effective A…

Using a pioneering artificial intelligence platform, Flinders University researchers have assessed whether a cardiac AI tool recently trialled in South Australian hospitals actually has the potential to assist doctors and...

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

AI Unlocks Genetic Clues to Personalize …

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes - insights that could help doctors tailor...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

Deep Learning to Increase Accessibility…

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...